Menu Search
Equities

Applied BioCode Corp

6598:TAI

Applied BioCode Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)22.80
  • Today's Change-0.150 / -0.65%
  • Shares traded131.29k
  • 1 Year change+16.79%
  • Beta--
Data delayed at least 20 minutes, as of Nov 25 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in TWDIncome statement in TWDView more

Year on year Applied BioCode Corp had relatively flat revenues (390.30m to 395.17m), though the company grew net income from a loss of 184.73m to a smaller loss of 164.20m. A reduction in the cost of goods sold as a percentage of sales from 40.00% to 31.99% was a component in the net income growth despite flat revenues.
Gross margin67.71%
Net profit margin-51.39%
Operating margin-56.80%
Return on assets-16.66%
Return on equity-24.56%
Return on investment-18.29%
More ▼

Cash flow in TWDView more

In 2023, cash reserves at Applied BioCode Corp fell by 418.13m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 205.09m for operations while cash used for investing totalled 198.02m.
Cash flow per share-1.52
Price/Cash flow per share--
Book value per share8.94
Tangible book value per share8.91
More ▼

Balance sheet in TWDView more

Applied BioCode Corp has little financial risk as the capital structure does not rely on leverage.
Current ratio11.30
Quick ratio9.37
Total debt/total equity0.0252
Total debt/total capital0.0246
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.